Some economics on personalized and predictive medicine

European Journal of Health Economics

Volumn 16, Issue 9, 2015, Pages 985-994

  Antonanzas F ^a   Juarez Castello C A ^a   Rodriguez Ibeas R ^a  

^a UNIVERSITY OF LA RIOJA   (Spain)

Author keywords

Economic model; Genetic testing; Personalized medicine; Predictive medicine; Sensitivity; Specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; COLORECTAL CANCER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FRAGILE X SYNDROME; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MEDICINE; NEWBORN SCREENING; ONCOGENE K RAS; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; GENETIC SCREENING; GENETICS; MALE; PROCEDURES; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY; STANDARDS; STATISTICAL MODEL;

COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FRAGILE X SYNDROME; GENETIC TESTING; HUMANS; MALE; MODELS, ECONOMETRIC; PRECISION MEDICINE; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY;

EID: 84947486936     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-014-0647-8     Document Type: Article

References (27)

1. Gibson, W.M.: Can personalized medicine survive? Can Fam Physician 17(8), 29–88 (1971)
2. Antoñanzas, F., Rodríguez-Ibeas, R., Hutter, M.F., Lorente, R., Juárez, C., Pinillos, M.: Genetic testing in the European Union: does economic evaluation matter? Eur J Health Econ 12(5), 651–662 (2012)
3. Payne, K.A., Frueh, F.W., Sohal, J.: Enhancing the health economic value of retrospective and prospective real-world studies with pharmacogenomic testing: opportunities and challenges associated with an integrated personalized medicine approach. Value Health 15(4), A159–A160 (2012)
4. Lester, D.S.: Will personalized medicine help in ‘transforming’ the business of healthcare? Pers Med 6(5), 555–565 (2009)
5. Lewis, J.R.R., Lipworth, W.L., Kerridge, I.H., Day, R.O.: The economic evaluation of personalised oncology medicines: ethical challenges. Med J Aust 199(7), 471–473 (2013)
6. Schildmann, J., Marckmann, G., Vollmann, J.: Personalized medicine. medical, ethical, legal, and economic analysis. Ethik in Der Med 25(3), 169–172 (2013)
7. Redekop, W.K., Mladsi, D.: The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health 16, 54–59 (2013)
8. Trusheim, M.R., Berndt, E.R., Douglas, F.L.: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 6(4), 287–293 (2007)
9. Kalia, M.: Personalized oncology: recent advances and future challenges. Metabolism 62(1), S11–S14 (2013)
10. Meckley, L.M., Neumann, P.J.: Personalized medicine: factors influencing reimbursement. Health Policy 94(2), 91–100 (2010)
11. Greeley, S.A.W., John, P.M., Winn, A.N., Ornelas, J., Lipton, R.B., Philpson, L.H., et al.: The cost-effectiveness of personalized genetic medicine the case of genetic testing in neonatal diabetes. Diabetes Care 34(3), 622–627 (2011)
12. Postma, M.J., Boersma, C., Vandijck, D., Vegter, S., Le, H.H., Annemans, L.: Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 11(4), 367–369 (2011)
13. Annemans, L., Redekop, K., Payne, K.: Current methodological issues in the economic assessment of personalized medicine. Value Health 16(6), S20–S26 (2013)
14. Sahlin, N., Hermeren, G.: Personalised, predictive and preventive medicine: a decision-theoretic perspective. J Risk Res 15(5), 453–457 (2012)
15. Chiappori, P.A.: The Welfare of Predictive Medicine, in Competitive Failures in Insurances Markets: Theory and Policy Implications, pp. 55–78. MIT Press, Cambridge (2006)
16. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F.: GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC cancerbase no. 11. Lyon, France: International Agency for Research on Cancer 2013. http://globocan.iarc.fr. Accessed 29 May 2014
17. National Institute for Health and Care Excellence (NICE): KRAS Mutation testing of tumours in adults with metastatic colorectal cancer: diagnostic assessment report. (2013). http://www.nice.org.uk/nicemedia/live/13937/65373/65373.pdf. Accessed 05 July 2014
18. Behl, A.S., et al.: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 104(23), 1785–1795 (2012)
19. Thierry, A.R., et al.: Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 20, 430–435 (2014)
20. Prostate Cancer Research Institute: PCA3: A genetic marker of prostate cancer. http://prostate-cancer.org/pca3-a-genetic-marker-of-prostate-cancer. Accessed 02 June 2014
21. Barbera, M., Pepe, P., Paola, Q., Aragona, F.: PCA3 score accuracy in diagnosing prostate cancer at repeat biopsy: our experience in 177 patients. Arch Ital Urol Androl 84(4), 227–229 (2012)
22. Bradley, L.A., Palomaki, G.E., Gutman, S., Samson, D., Aronson, N.: Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol 190(2), 389–398 (2013)
23. Federación Española del Síndrome X Frágil: ¿Qué es el Sindrome X-frágil? http://www.xfragil.com/sin.htm. Accessed 06 Feb 2014
24. Weck, K.E., Zehnbauer, B., Datto, M., Schrijver, I.: Molecular genetic testing for fragile X syndrome: laboratory performance on the College of American Pathologists proficiency surveys (2001–2009). Genet Med 14(3), 306–312 (2012)
25. Towse, A., Garrison, L.P.: Economic incentives for evidence generation: promoting an efficient path to personalized medicine. Value Health 16(6), S39–S43 (2013)
26. O’Donnell, J.C.: Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research. Value Health 16(6), S1–S3 (2013)
27. Rogowski, W., Payne, K., Schnell-Inderst, P., Manca, A., Rochau, U., Jahn, B., et al.: Concepts of "Personalization" in personalized medicine: implications for economic evaluation. PharmacoEconomics. (2014). doi:10.1007/s40273-014-0211-5